Breast And Ovarian Cancers
Genta's Decoy Program Suppresses Key Cancer Genes In Breast and Ovarian Cancer
Published in Drug Week, November 9th, 2001
Genta Inc. has announced the publication of two scientific papers that show an important pipeline drug downregulated key cancer genes and exerted potent preclinical antitumor activity in breast and ovarian cancer. Using the Company's lead compound from its "Decoy Aptamer" program, the new papers derive from the laboratory of Dr. Yoon S. Cho-Chung from the U.S. National Cancer Institute. Genta holds an exclusive license to this technology.
"Decoy" technology involves using short DNA sequences to target proteins known as "transcription factors" that normally bind specific sequences in genomic DNA, thereby regulating downstream production of a protein. "Decoys" attach...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2001-11-09)
More Articles from Drug Week
- Drug Development
Oral Delivery Of Insulin Deemed Safe, Nontoxic In Animal Studies - Tuberculosis Therapy
Intermittent Streptomycin Doses May Increase Efficacy - AIDS and HIV Therapy
Abacavir Pharmacokinetics Unaffected By Renal Impairment - Adverse Drug Effects
Infliximab Can Increase Tuberculosis Risk - Drug Development
Novel Anticancer Drugs Selectively Activate Apoptosis - Drug Safety
Acetaminophen Not Linked To Liver Injury In Alcoholics - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
